Morgan Stanley raises Vital Farms stock price target to $48 on growth outlook

Morgan Stanley raised its price target for Vital Farms (VITL) to $48 from $41, maintaining an Overweight rating, citing an underappreciated "outsized topline growth opportunity" driven by shifting consumer preferences and distribution expansion. This follows Vital Farms' strong Q2 2025 results, which exceeded expectations with $185 million in revenue and $0.36 adjusted EPS, alongside 15% volume growth. The positive performance and outlook have also led BMO Capital and Telsey Advisory Group to raise their price targets to $50, signaling broad analyst confidence in the specialty egg producer's continued growth trajectory.

Analysis

Vital Farms (VITL) is demonstrating significant operational momentum, validated by a strong second-quarter 2025 performance and a chorus of positive analyst revisions. The company substantially exceeded expectations with revenue of $185 million, surpassing the consensus forecast of $171 million, driven by a robust 15% year-over-year volume growth and overall sales growth of 25.4%. Profitability was also a key highlight, as adjusted earnings per share of $0.36 comfortably beat the FactSet consensus of $0.28. This performance has prompted several investment banks to reassess their outlook. Morgan Stanley raised its price target to $48, citing an underappreciated growth opportunity and projecting a 21% three-year revenue CAGR from 2025-2027. This upgrade included a valuation multiple expansion to 16.5x, supported by increased fiscal 2025 and 2026 estimates for both revenue and EBITDA. The bullish sentiment is shared across the street, with BMO Capital and Telsey Advisory Group also raising their price targets to $50. The core drivers for this optimism are identified as favorable shifts in consumer preferences toward specialty eggs and Vital Farms' ongoing success in expanding its distribution network.

Key Decisions for Investors

• Given the substantial earnings and revenue beat, alongside unanimous price target upgrades from analysts, investors may consider the current environment a strong validation of a long-term bullish thesis for Vital Farms.
• The impressive 15% year-over-year volume growth is a critical indicator of strong consumer demand and successful market penetration, suggesting the company's growth narrative is intact and supportive of potential new positions.
• Investors should monitor the company's ability to sustain this growth trajectory and protect margins in future quarters to ensure it can justify the higher 16.5x valuation multiple cited by Morgan Stanley.